Plain-English translation of NCT07017686 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Arthritis, Rheumatoid research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is an early-stage safety study of abdominal vagus nerve stimulation (aVNS), a device implanted during a small surgery that gently stimulates a major nerve in your abdomen. The trial will enroll 5 adults with moderate to severe rheumatoid arthritis that hasn't improved with at least two types of strong biologic medications. Researchers want to understand whether this treatment is safe and whether it might reduce joint pain and swelling.
Many people with rheumatoid arthritis don't get relief from current standard medications, and they need new options. Recent research suggests that stimulating the vagus nerve may help calm the body's inflammatory response, which drives arthritis. This trial is exploring whether this approach could become a new treatment choice for people whose disease hasn't responded to other therapies.
You likely qualify if…
You likely don't qualify if…
You would have a minor surgical procedure to place the small stimulation device in your abdomen. After surgery, you would turn the device on and off yourself for 3 hours each day using a controller. You would visit the clinic at 2 weeks, 6 weeks, 12 weeks, and 24 weeks to have the device checked and your arthritis symptoms assessed. If the treatment seems safe and helpful, you could choose to continue using it, with follow-up visits twice per year for up to 5 years total.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Australia